Noriyuki Masuda
Overview
Explore the profile of Noriyuki Masuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanaka H, Mukai J, Kushibiki K, Mizushima S, Maeda K, Fujimoto Y, et al.
Vaccine
. 2022 Dec;
41(2):365-371.
PMID: 36460533
Purpose: Administration of three doses of Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine was completed in Japan in the spring of 2022. This study aimed to evaluate the antibody responses, and kinetics...
2.
Okimoto R, Ino K, Ishizu K, Takamatsu H, Sakamoto K, Yuyama H, et al.
Low Urin Tract Symptoms
. 2022 Feb;
14(4):289-300.
PMID: 35150075
Objectives: Muscarinic M (M ) receptors mediate cholinergic smooth muscle contraction of the bladder. Current drugs targeting bladder M receptors for micturition disorders have a risk of cholinergic side effects...
3.
Okimoto R, Ino K, Ishizu K, Takamatsu H, Sakamoto K, Yuyama H, et al.
J Pharmacol Exp Ther
. 2021 Jul;
379(1):64-73.
PMID: 34244231
Muscarinic M (M) receptors mediate a wide range of acetylcholine (ACh)-induced functions, including visceral smooth-muscle contraction and glandular secretion. Positive allosteric modulators (PAMs) can avoid various side effects of muscarinic...
4.
Yamamoto N, Harada H, Okamoto I, Masuda N, Hayakawa K, Satouchi M, et al.
Clin Lung Cancer
. 2021 Feb;
22(2):134-141.
PMID: 33518480
Background: We evaluated the tolerability and efficacy of nimotuzumab, a humanized IgG1 monoclonal anti-epidermal growth factor receptor antibody, with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small-cell lung cancer....
5.
Otani S, Sasaki J, Nakahara Y, Fukui T, Igawa S, Naoki K, et al.
Invest New Drugs
. 2020 Nov;
39(2):530-536.
PMID: 33159674
Background Amrubicin (AMR) is a completely synthetic 9-aminoanthracycline and clinically active against non-small cell lung cancer (NSCLC). We conducted a phase I study of AMR and erlotinib (ERL) combination therapy...
6.
Kubota K, Kunitoh H, Seto T, Shimada N, Tsuboi M, Ohhira T, et al.
Lung Cancer
. 2020 Jan;
141:32-36.
PMID: 31931444
Objective: Adjuvant chemotherapy is standard of care for patients with completely resected stage IB, II and IIIA NSCLC. However, optimum chemotherapy regimen has not been determined. TORG0503 was undertaken to...
7.
Hiyoshi Y, Sato Y, Ichinoe M, Nagashio R, Hagiuda D, Kobayashi M, et al.
Thorac Cancer
. 2019 Oct;
10(11):2142-2151.
PMID: 31583841
Background: Mitochondrial dysfunction contributes to many types of human disorders and cancer progression. Inner membrane mitochondrial protein (IMMT) plays an important role in the maintenance of mitochondrial structure and function....
8.
Ota T, Masuda N, Matsui K, Yamada T, Tanaka N, Fujimoto S, et al.
Intern Med
. 2019 Jun;
58(18):2651-2655.
PMID: 31178493
Crizotinib has been approved for patients with advanced lung adenocarcinoma harboring rearrangements of the c-ROS-1 (ROS1) and anaplastic lymphoma kinase (ALK) genes. We report a patient with ROS1-rearranged lung adenocarcinoma...
9.
Ishigami T, Ueshima K, Ukai M, Asai N, Takamatsu H, Yokono M, et al.
J Pharmacol Sci
. 2019 Mar;
139(4):333-339.
PMID: 30871873
The pharmacological profile of ASP2205 fumarate (ASP2205), a novel 5-HT receptor agonist, was evaluated in vitro and in vivo. ASP2205 showed potent and selective agonistic activity for the human 5-HT...
10.
Sakamoto K, Noguchi Y, Ueshima K, Ohtake A, Sato S, Imazumi K, et al.
Eur J Pharmacol
. 2019 Mar;
853:11-17.
PMID: 30853531
Bladder dysfunctions associated with benign prostatic hyperplasia are not sufficiently alleviated by current pharmacotherapies. Lysophosphatidic acid (LPA) is a phospholipid with diverse biological effects. LPA modulates prostate and urethral contraction...